denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Why Am I Getting Paged at 2AM? Microangiopathic Emergencies
Hematology Disease Topics & Pathways:
Bleeding and Clotting, autoimmune disorders, Biological therapies, Antibody Therapy, adult, Clinical Practice (Health Services and Quality), pediatric, Diseases, Immune Disorders, thrombotic disorders, Therapies, Technology and Procedures, Study Population, Human
Session: Why Am I Getting Paged at 2AM? Microangiopathic Emergencies
Hematology Disease Topics & Pathways:
Bleeding and Clotting, autoimmune disorders, Biological therapies, Antibody Therapy, adult, Clinical Practice (Health Services and Quality), pediatric, Diseases, Immune Disorders, thrombotic disorders, Therapies, Technology and Procedures, Study Population, Human
Saturday, December 9, 2023, 4:00 PM-5:15 PM
Disclosures: Chaturvedi: Alexion: Consultancy, Other: Advisory board participation; Sanofi Genzyme: Consultancy; Sobi: Honoraria; Sanofi: Other: Advisory board participation; Takeda: Other: Advisory board participation.
OffLabel Disclosure: I will discuss the off label use of rituximab in immune TTP and eculizumab/ravulizumab in secondary thrombotic microangiopathy
See more of: Why Am I Getting Paged at 2AM? Microangiopathic Emergencies
See more of: Education Program
See more of: Education Program